By composing a systematic review of randomized clinical trials of patients with advanced melanoma, researchers were able to demonstrate that the risk for immune-related adverse effects (irAEs) is directly correlated with immune checkpoint inhibitor type. The meta-analysis, put together by Chin Yuang Chang, MS, Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, and colleagues, sought to evaluate the various risks for melanoma patients receiving different treatments.

Learn more by clicking here.